oncolytics biotech inc (ONCY) Key Developments
Oncolytics Biotech Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase II Pancreatic Cancer Study
Jul 8 14
Oncolytics Biotech Inc. announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045). The principal investigator is Tanios Bekaii-Saab, MD, associate professor and gastrointestinal oncology section chief at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James). The trial is sponsored by the U.S. National Cancer Institute (NCI) through a clinical trials agreement between the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis and Oncolytics. Oncolytics is providing clinical supplies of REOLYSIN for the study. The study is an open-label, multi-institution, two-arm phase II randomized study of patients with metastatic pancreatic cancer. Patients were randomized to receive either carboplatin, paclitaxel plus REOLYSIN (Arm A) or carboplatin and paclitaxel alone (Arm B). Patients in both arms received treatment every three weeks (21-day cycles) and standard intravenous doses of paclitaxel and carboplatin on day one only. In Arm A, patients also received intravenous REOLYSIN at a dose of 3x1010 TCID50 on days one through five. Tumor response assessment was done by computed tomography (CT) scan and conducted every eight weeks. Patients who progressed on carboplatin and paclitaxel (Arm B) had REOLYSIN added. If patients experienced significant toxicity related to carboplatin and/or paclitaxel, they could continue with single agent REOLYSIN. The primary objective of the trial is to assess improvement in progression-free survival with REOLYSIN, carboplatin and paclitaxel relative to carboplatin and paclitaxel alone in patients with metastatic pancreatic cancer. The primary endpoint is progression free survival in both arms. Secondary endpoints include overall response rate and overall survival. The study enrolled 70 evaluable patients at test centers across the United States.
Oncolytics Biotech Inc. Elects Linda Hohol and Angela Holtham as Directors
Jun 19 14
Oncolytics Biotech Inc. elected Linda Hohol and Angela Holtham as directors of the company at the Annual Meeting of Shareholders held on June 18, 2014.
Oncolytics Biotech Inc. - Shareholder/Analyst Call
Jun 16 14
To discuss the recent progress in the development of REOLYSIN as a potential cancer therapeutic
Oncolytics Biotech Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 11:00 AM
Jun 14 14
Oncolytics Biotech Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 11:00 AM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada.
Oncolytics Biotech Inc. Announces Director Changes
May 22 14
Oncolytics Biotech Inc. announced the nomination of Ms. Linda Hohol and Ms. Angela Holtham to its slate of directors for election by shareholders at its upcoming Annual General Meeting to be held June 18, 2014 in Toronto, Ontario, Canada. The Company also announced that Fred Stewart, QC will not be standing for re-election at this year's meeting. Over a 26-year career with CIBC, Ms. Hohol held progressively senior retail and commercial banking positions before advancing to the role of Executive Vice President, Wealth Management. Most recently she was President of the TSX Venture Exchange where she was instrumental in raising the profile of the Exchange as a means for small and medium market capitalization companies to access capital, while also driving improved financial performance of the organization. Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer.